IL265796B2 - Preparations comprising short peptides derived from PEDF and their uses - Google Patents

Preparations comprising short peptides derived from PEDF and their uses

Info

Publication number
IL265796B2
IL265796B2 IL265796A IL26579619A IL265796B2 IL 265796 B2 IL265796 B2 IL 265796B2 IL 265796 A IL265796 A IL 265796A IL 26579619 A IL26579619 A IL 26579619A IL 265796 B2 IL265796 B2 IL 265796B2
Authority
IL
Israel
Prior art keywords
pdsp
peptide
seq
cells
pharmaceutical composition
Prior art date
Application number
IL265796A
Other languages
English (en)
Hebrew (he)
Other versions
IL265796B1 (en
IL265796A (en
Original Assignee
Brim Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brim Biotechnology Inc filed Critical Brim Biotechnology Inc
Publication of IL265796A publication Critical patent/IL265796A/en
Publication of IL265796B1 publication Critical patent/IL265796B1/en
Publication of IL265796B2 publication Critical patent/IL265796B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL265796A 2016-10-07 2017-08-24 Preparations comprising short peptides derived from PEDF and their uses IL265796B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662405522P 2016-10-07 2016-10-07
PCT/US2017/048340 WO2018067244A1 (en) 2016-10-07 2017-08-24 Compositions comprising pedf-derived short peptides and uses thereof

Publications (3)

Publication Number Publication Date
IL265796A IL265796A (en) 2019-06-30
IL265796B1 IL265796B1 (en) 2024-10-01
IL265796B2 true IL265796B2 (en) 2025-02-01

Family

ID=61831898

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265796A IL265796B2 (en) 2016-10-07 2017-08-24 Preparations comprising short peptides derived from PEDF and their uses

Country Status (10)

Country Link
US (1) US11760784B2 (enExample)
EP (1) EP3596104A4 (enExample)
JP (2) JP7573967B2 (enExample)
KR (2) KR20230169375A (enExample)
CN (1) CN110312732A (enExample)
AU (2) AU2017340245B2 (enExample)
EA (1) EA037698B1 (enExample)
IL (1) IL265796B2 (enExample)
TW (1) TWI878203B (enExample)
WO (2) WO2018067244A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277689B2 (en) * 2018-04-08 2024-12-01 Brim Biotechnology Inc Application of pedf-derived short peptides in tendon healing
US20210221862A1 (en) * 2018-04-08 2021-07-22 Brim Biotechnology, Inc. Application of pedf-derived short peptides in the treatment of osteoarthritis
EP3773493A4 (en) * 2018-05-04 2022-03-30 Brim Biotechnology, Inc. PEDF DERIVED PEPTIDES TO PROMOTE MEIBOMIUS GLAND REGENERATION AND THEIR USES
CN111632128B (zh) * 2019-02-14 2022-07-05 三凡生技研发股份有限公司 短链胜肽组合物在预防或治疗干眼症的应用
TWI759610B (zh) * 2019-06-27 2022-04-01 晶碩光學股份有限公司 具有角膜修護功能的眼用產品
US12221494B2 (en) * 2019-08-27 2025-02-11 Mackay Memorial Hospital Short synthetic peptides and their uses for treating retinal degenerative diseases and/or tissue injuries
TWI744683B (zh) * 2019-08-27 2021-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途
CN115151243A (zh) * 2019-10-06 2022-10-04 全福生物科技股份有限公司 包含pedf-衍生短肽(pdsp)的组合物及其用途
CN112206312A (zh) * 2020-11-19 2021-01-12 北京大学第三医院（北京大学第三临床医学院） 一种包含pedf的用于治疗干眼的药物组合物
CN115364199A (zh) * 2021-05-19 2022-11-22 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途
KR20250023387A (ko) * 2022-06-13 2025-02-18 브림 바이오테크놀로지, 인코퍼레이티드 안구 건조증 질환 치료를 위한 pedf 유래 짧은 펩타이드를 포함하는 조성물
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095350A2 (en) * 2006-02-15 2007-08-23 Yale University Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
WO2011044216A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
US20120245097A1 (en) * 2011-03-23 2012-09-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for promoting stem cells proliferation and wound healing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
CN101014358A (zh) * 2003-10-29 2007-08-08 约翰·霍普金斯大学 色素上皮所衍生因子的生物活性及使用方法
WO2005089811A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye
EP2271760A2 (en) * 2008-04-29 2011-01-12 Monsanto Technology LLC Genes and uses for plant enhancement
TWI554521B (zh) * 2011-10-19 2016-10-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
AU2012387503B2 (en) * 2012-08-09 2016-11-03 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis
AU2012390200B2 (en) * 2012-09-19 2017-06-29 Mackay Memorial Hospital Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging
WO2014043871A1 (en) * 2012-09-20 2014-03-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for treating osteoarthritis
WO2015038891A2 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional peptide analogs of pedf

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095350A2 (en) * 2006-02-15 2007-08-23 Yale University Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
WO2011044216A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
US20120245097A1 (en) * 2011-03-23 2012-09-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for promoting stem cells proliferation and wound healing
EP2508196A1 (en) * 2011-03-23 2012-10-10 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIUCHENG HE ET AL., " THE PEDF NEUROPROTECTIVE DOMAIN PLUS DHA INDUCES CORNEAL NERVE REGENERATION AFTER EXPERIMENTAL SURGERY", 1 June 2015 (2015-06-01) *
TSUNG-CHUAN HO ET AL., " PEDF PROMOTES SELF-RENEWAL OF LIMBAL STEM CELL AND ACCELERATES CORNEAL EPITHELIAL WOUND HEALING: PEDF ASSISTS LIMBAL STEM CELL EXPANSION", 1 September 2013 (2013-09-01) *
YU MAN ET AL., " TOPICAL PIGMENT EPITHELIUM-DERIVED FACTOR SUPPRESSES CORNEAL EPITHELIOPATHY AND INFLAMMATION IN DRY EYE DISEASE", 6 June 2017 (2017-06-06) *

Also Published As

Publication number Publication date
JP7573967B2 (ja) 2024-10-28
AU2022204557A1 (en) 2022-07-21
WO2018067217A2 (en) 2018-04-12
AU2017340245A1 (en) 2019-05-23
EA037698B1 (ru) 2021-05-12
IL265796B1 (en) 2024-10-01
CN110312732A (zh) 2019-10-08
EP3596104A4 (en) 2021-02-17
WO2018067217A3 (en) 2019-05-02
EA201990885A1 (ru) 2019-08-30
US20190248859A1 (en) 2019-08-15
AU2017340245B2 (en) 2022-07-21
US11760784B2 (en) 2023-09-19
TW201822785A (zh) 2018-07-01
KR20190066030A (ko) 2019-06-12
WO2018067244A1 (en) 2018-04-12
KR20230169375A (ko) 2023-12-15
JP2022185042A (ja) 2022-12-13
JP2019533722A (ja) 2019-11-21
TWI878203B (zh) 2025-04-01
IL265796A (en) 2019-06-30
EP3596104A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
US11760784B2 (en) Compositions comprising PEDF-derived short peptides and uses thereof
Upadhyay et al. Oxidative stress in the retina and retinal pigment epithelium (RPE): Role of aging, and DJ-1
Chen et al. Efficacy of osmoprotectants on prevention and treatment of murine dry eye
CA2931039A1 (en) Compositions and methods for treatment of ocular inflammation and pain
JP2020038211A (ja) 眼の感染症および疾患を処置するための組成物および方法
Lin et al. Serine protease inhibitor A3K suppressed the formation of ocular surface squamous metaplasia in a mouse model of experimental dry eye
Gu et al. Dimethyl fumarate ameliorates fungal keratitis by limiting fungal growth and inhibiting pyroptosis
Shi et al. Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against renal ischemia-reperfusion injury
Li et al. Effects of topical mucolytic agents on the tears and ocular surface: a plausible animal model of mucin-deficient dry eye
Zhou et al. Rosmarinic acid-grafted gelatin nanogels for efficient diquafosol delivery in dry eye disease therapy
Xu et al. The increased activity of a transcription factor inhibits autophagy in diabetic embryopathy
Chen et al. Aim2 deficiency ameliorates lacrimal gland destruction and corneal epithelium defects in an experimental dry eye model
US20240156783A1 (en) Eye drops to treat chemically induced corneal damage
EP4241781A1 (en) Use of p55pik inhibitor in preparation of drug for treating dry eye disease
Li et al. Therapeutic effect and mechanism of action of pterostilbene nano drugs in dry eye models
KR101810156B1 (ko) 폴리에틸렌 글리콜 및 플라보노이드 나노복합체를 유효성분으로 함유하는 안구 건조증 예방 또는 치료용 조성물
Zhao et al. BMSC reduces ROS and inflammation levels by inhibiting TLR4/MYD88/NF-κB signaling axis to alleviate dry eye
JP7759950B2 (ja) 眼表面疾患の治療方法
El Shazly et al. Potential prophylactic role of aminoguanidine in diabetic retinopathy and nephropathy in experimental animals
Kulualp et al. Therapeutic effect of bovine amniotic fluid in murine dry eye model
US20080032958A1 (en) Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development
Liu et al. Mitochondrial-Derived Peptide MOTS-c Targets SLC7A11 to Preserve Spermatogenesis by Suppressing Ferroptosis
Ratay Controlled Release of an HDAC Inhibitor for Reduction of Inflammation in Dry Eye Disease Michelle L. Ratay, Stephen C. Balmert, Ethan J. Bassin c, and Steven R. Little
CN108430496A (zh) 用于治疗角膜病症的蛋白酶体调节